908 Devices Inc

NASDAQ:MASS USA Medical Devices
Market Cap
$225.12 Million
Market Cap Rank
#16913 Global
#6466 in USA
Share Price
$6.22
Change (1 day)
+2.13%
52-Week Range
$3.63 - $9.15
All Time High
$75.00
About

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices for use in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of… Read more

908 Devices Inc (MASS) - Net Assets

Latest net assets as of December 2025: $143.70 Million USD

Based on the latest financial reports, 908 Devices Inc (MASS) has net assets worth $143.70 Million USD as of December 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($190.07 Million) and total liabilities ($46.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $143.70 Million
% of Total Assets 75.6%
Annual Growth Rate N/A
5-Year Change -33.04%
10-Year Change N/A
Growth Volatility 30.73

908 Devices Inc - Net Assets Trend (2018–2025)

This chart illustrates how 908 Devices Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for 908 Devices Inc (2018–2025)

The table below shows the annual net assets of 908 Devices Inc from 2018 to 2025.

Year Net Assets Change
2025-12-31 $143.70 Million +25.40%
2024-12-31 $114.59 Million -30.76%
2023-12-31 $165.49 Million -13.17%
2022-12-31 $190.60 Million -11.19%
2021-12-31 $214.60 Million +54.35%
2020-12-31 $139.04 Million +320.11%
2019-12-31 $-63.17 Million -25.89%
2018-12-31 $-50.18 Million --

Equity Component Analysis

This analysis shows how different components contribute to 908 Devices Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 17104000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock $36.00K 0.03%
Other Comprehensive Income $54.00K 0.04%
Other Components $366.93 Million 255.34%
Total Equity $143.70 Million 100.00%

908 Devices Inc Competitors by Market Cap

The table below lists competitors of 908 Devices Inc ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in 908 Devices Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 114,592,000 to 143,699,000, a change of 29,107,000 (25.4%).
  • Net income of 19,489,000 contributed positively to equity growth.
  • Other comprehensive income decreased equity by 1,092,000.
  • Other factors increased equity by 10,710,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $19.49 Million +13.56%
Other Comprehensive Income $-1.09 Million -0.76%
Other Changes $10.71 Million +7.45%
Total Change $- 25.40%

Book Value vs Market Value Analysis

This analysis compares 908 Devices Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.68x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2018-12-31 $-6.18 $6.22 x
2019-12-31 $-8.39 $6.22 x
2020-12-31 $25.35 $6.22 x
2021-12-31 $7.68 $6.22 x
2022-12-31 $6.05 $6.22 x
2023-12-31 $5.13 $6.22 x
2024-12-31 $3.36 $6.22 x
2025-12-31 $3.69 $6.22 x

Capital Efficiency Dashboard

This dashboard shows how efficiently 908 Devices Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 13.56%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 34.68%
  • • Asset Turnover: 0.30x
  • • Equity Multiplier: 1.32x
  • Recent ROE (13.56%) is above the historical average (-13.46%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2018 0.00% -34.17% 0.79x 0.00x $-2.52 Million
2019 0.00% -74.41% 0.48x 0.00x $-7.06 Million
2020 -9.22% -47.66% 0.15x 1.29x $-26.72 Million
2021 -10.33% -52.53% 0.16x 1.22x $-43.63 Million
2022 -16.65% -67.75% 0.19x 1.27x $-50.80 Million
2023 -21.99% -72.47% 0.25x 1.23x $-52.95 Million
2024 -63.01% -121.09% 0.37x 1.39x $-83.67 Million
2025 13.56% 34.68% 0.30x 1.32x $5.12 Million

Industry Comparison

This section compares 908 Devices Inc's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $694,749,556
  • Average return on equity (ROE) among peers: -25.46%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
908 Devices Inc (MASS) $143.70 Million 0.00% 0.32x $135.59 Million
Advanced Biomedical Technologies Inc (ABMT) $-4.46 Million 0.00% 0.00x $14.18K
Abbott Laboratories (ABT) $4.82 Billion 39.04% 1.31x $191.37 Billion
Acarix AB (publ) (ACIXF) $1.93 Million -127.02% 0.21x $26.42 Million
Adagio Medical Holdings, Inc Common Stock (ADGM) $-72.62 Million 0.00% 0.00x $4.05 Million
Adm Tronics Unltd (ADMT) $-12.69K 0.00% 0.00x $3.17 Million
Aethlon Medical Inc (AEMD) $-3.07 Million 0.00% 0.00x $2.79 Million
Acutus Medical Inc (AFIB) $126.58 Million -80.56% 0.52x $732.88K
Adapthealth Corp (AHCO) $2.07 Billion 7.56% 1.54x $914.25 Million
Allied Healthcare Products Inc. (AHPIQ) $8.88 Million -33.95% 1.22x $726.24
20/20 Biolabs, Inc. Common Stock (AIDX) $3.39 Million -59.65% 0.38x $9.18 Million